Physician profile
Sandra George
NPI 1073997789
$1,772.59
in general payments reported to CMS, 2019-2025
13 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2024: $1,326 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $290.08 | 2025 | Tepezza, Krystexxa |
| Si-Bone, INC. | $244.05 | 2024 | |
| Inspire Medical Systems, INC. | $149.92 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $140.00 | 2024 | Austedo Xr |
| Madrigal Pharmaceuticals | $127.72 | 2024 | Rezdiffra |
| Axsome Therapeutics, INC. | $124.99 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2024 | Xifaxan |
| Ultragenyx Pharmaceutical INC. | $123.78 | 2022 | |
| Phathom Pharmaceuticals, INC. | $121.77 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $118.41 | 2024 | Farxiga |
| Gilead Sciences, INC. | $116.71 | 2024 | Livdelzi |
| Janssen Pharmaceuticals, INC | $57.70 | 2024 | Spravato |
| Acadia Pharmaceuticals INC | $32.48 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.